SUMMARY -Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract and are generally asymptomatic. A 39-year-old female patient was hospitalized in 2012 at Clinical Department of Internal Medicine, Sestre milosrdnice University Hospital Center, for a focal hypodense irregular circular lesion located in segment III of the left hepatic lobe, accidentally found by ultrasonography and verifi ed by computed tomography. Th e fi ndings were also verifi ed with nuclear magnetic resonance and esophagogastroduodenoscopy. A biopsy sample of the lesion was analyzed by histologic and immunohistochemical methods and identifi ed as GIST. Th e patient underwent surgical operation (tumor excision with terminoterminal anastomosis created between the second segment of duodenum and jejunum and resection of liver segment III). Th e histopathologic fi ndings matched GIST with a high probability of relapse according to the localization, size, mitotic activity and Ki-67 values. Th erefore, therapy with imatinib at a dose of 400 mg/day was administered. Th ree years after the operation, the patient is still in remission.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract and are generally asymptomatic, but they make only 1% of primary tumors of the gastrointestinal (GI) tract. GISTs are usually accidentally found during endoscopic or radiologic procedures. After immunohistochemical analysis, Hirota et al.
1 discovered connection between GIST and Cajal intestinal cells and their predecessors. Th e incidence of GIST is 6.8-14.5/ million [2] [3] [4] [5] , it occurs at a median age of 63 and men are aff ected more commonly (55%). In 80% of cases, a KIT-gene mutation is found, 15% are considered as a wild-type mutation and 5% are KIT-negative PDFRA-positive mutation 6 . Th e two most common primary sites are stomach (60%-75%) and small intestine (20%-30%). GIST shows extraluminal growth, but it does not infi ltrate local organs. About 10%-25% of patients have metastases, most common in the liver and peritoneum. Diagnostic algorithm consists of multi-slice computed tomography (MSCT), magnetic resonance imaging (MRI), ultrasonography, endoscopic ultrasonography, positron emission tomography-computed tomography (PET CT), histopathologic and immunohistochemical methods. Primary treatment is surgical procedure with adjuvant pharmacotherapy with imatinib.
Case Report
A 39-year-old female patient treated for iron-deficiency anemia since 2006 was hospitalized in 2012 at Clinical Department of Internal Medicine, Sestre milosrdnice University Hospital Center. She came from another facility for planned aspiration biopsy of CTverifi ed focal hypodense irregular circular lesion with an approximately 3-cm diameter located in segment III of the left hepatic lobe. Transabdominal ultrasound (Fig. 1a, b) revealed a tumorous ring-shaped lesion, in addition to prior CT-verifi ed lesion, with a diameter of 42 mm on the right paravertebral side in the projection of the duodenum, which was confi rmed by nuclear MRI (Fig. 2a, b) . Her symptoms in the past 6 months were postprandial pain in the right upper quadrant and weight loss (5 kg). She had slightly lower hemoglobin, hematocrit and mean corpuscular volume (MCV) with slightly elevated alfa 1 protein in plasma electrophoresis. Esophagogastroduodenoscopy (EGD) of the postbulbar duodenal segment (transition between segment II and segment III) was performed and showed a circular yellowish proliferative lesion which narrowed down the lumen to about 10 mm. A biopsy sample of the lesion was analyzed by histologic and immunohistochemical methods and identifi ed as GIST (Fig. 3a, b ). An operation was per- formed (5 cm large tumor excision and resection of segment III, segment IV and partial resection of distal segment II of duodenum with terminoterminal anastomosis created between second segment of duodenum and jejunum and resection of liver segment III). Th e histopathologic fi ndings matched GIST with a high probability of relapse according to the localization, size, mitotic activity and Ki-67 values. Th erefore, therapy with imatinib at a dose of 400 mg/day was administered. Th ree years after the operation, the patient is still in remission.
Discussion
Abdominal ultrasonography and EGD are mentioned as primary diagnostic methods in GIST diagnostics. Th ey are usually performed because of abdominal pain or palpable masses within the abdomen. When the initial suspicion of GIST is set, MSCT is the main imaging method for diagnosing both primary tumor and possible metastases, but sometimes GIST can be suspected just on ultrasonography. PET CT can be useful in determining hidden metastases 7 , but GIST may be present without signifi cant metabolic activity. EGD is used to describe tumor morphology, possible strictures in the GI tract, and to take biopsy samples. In our case, postbulbar duodenum was infi ltrated with a circular, yellowish lesion which narrowed it to 0.8 cm. Endoscopic ultrasonography (EUS) is the best method to diff erentiate GIST from leiomyoma. Leiomyoma and GIST have their origin in the 2 nd and 4 th hypoechoic layer, respectively. GIST has distorted shape, lobulation, irregular borders and increased echogenicity in comparison with the surrounding muscle echo, inhomogeneous pattern (inhomogeneity, hyperechoic posts, anechoic area), marginal halo and extraluminal growth pattern. Other signs that indicate malignancy are tumors bigger than 3 cm with irregular edges. In addition to EUS, EUS elastography with dominantly quantitative analysis (relatively heterogeneous 'hard' appearance without display of areas of necrosis by elastography software) can be performed and the strain ratio index measured. GIST has a high strain ratio index and therefore cannot be compressed. Contrast-enhanced EUS (CE-EUS) can demonstrate perfusion characteristics of subepithelial lesion and therefore can be used to diff erentiate GIST from other benign tumors (lipoma or leiomyoma) based on the hyper-enhanced appearance of GIST. CE-EUS has been recently used for assessment of tumor vascularity in order to predict the preoperative malignancy risk of GISTs through identifi cation of irregular vessels. With the EUS method, safe thin-needle biospy can be performed 8 to obtain samples for histopathologic and molecular analysis. Table 1 shows complete histologic analysis of GIST.
After that, classifi cation of stages and risk determination according to one of the classifi cations must be done. All these classifi cations have a purpose to determine high, intermediate or low risk GIST. According to the US National Institutes of Health, 44% of GIST are high risk, 23.6% intermediate risk and 32.4% low risk. In our case, the patient was classifi ed in the high risk group. Treatment of GIST is multidisciplinary through cooperation of surgeon, pathologist and oncologist 9, 10 . Complete surgical removal is recommended. In the treatment of inoperable or metastatic GIST, imatinib at a dose of 400 mg/day is used. In case of disease progression, the dose can be increased to 800 mg/day of imatinib. In patients with high and intermediate risk GIST, 400 mg/day imatinib therapy is recommended, as in our patient. In patients with inoperable or metastatic imatinib-resistant GIST, sutinib 11 can be used as second line therapy. Th ere are other promising drugs in clinical trials such as nilotinib, masitinib, dasatinib, sorafenib, vatalanib and combination of imatinib with RAD001-everolimus 12, 13 .
Conclusion
Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract, which account for only 1% of all primary tumors of the GI tract 14, 15 , and they are often diagnosed accidentally. Initial suspicion of GIST can be set by ultrasonography, but the main diagnostic methods are MSCT and EUS 16 .
